Table 4 Outcome measures at baseline and 6 months, N = 28
Outcome measure | Baseline (T1) Mean (SD) | 6 months (T2) Mean (SD) | Baseline to 6 months (T2–T1) mean difference (SD) | t (p) | 95% confidence interval | |
|---|---|---|---|---|---|---|
Lower | Upper | |||||
Pain (PACSLAC-II) | 6.0 (5.0) | 5.3 (3.8) | − 0.7 (4.3) | 0.82 (0.42) | − 0.97 | 2.26 |
Quality of life (QUALID) | 26.4 (8.9) | 24.7 (10.3) | − 1.7 (10.9) | 0.86 (0.40) | − 2.35 | 5.77 |
Medication costs ($) | 64.8 (58.1) | 59.0 (52.5) | − 5.8 (53.6) | 1.21 (0.24) | − 4.01 | 15.59 |
MQS benzodiazepine use | 0.3 (1.0) | 0.00 (0.0) | − 0.3 (1.0) | 1.44 (0.16) | − 0.12 | 0.68 |
MQS antidepressant use | 2.9 (3.3) | 2.5 (3.3) | − 0.4 (3.3) | 1.89 (0.05) | 0.04 | 0.83 |
MQS antipsychotic use | 1.4 (3.3) | 1.4 (2.8) | 0.0 (3.1) | 0.00 (1.00) | − 0.76 | 0.76 |
MQS acetaminophen use | 3.1 (2.3) | 3.2 (2.5) | 0.1 (2.5) | − 0.63 (0.53) | − 0.76 | 0.40 |
MQS NSAID use | 1.2 (2.7) | 1.1 (2.8) | − 0.1 (2.7) | 0.44 (0.66) | − 0.44 | 0.69 |
MQS opioid use | 2.1 (3.1) | 2.8 (4.4) | 0.7 (4.5) | − 1.07 (0.30) | − 2.19 | 0.69 |
MQS-III total score | 15.8 (11.6) | 15.1 (10.8) | − 0.7 (11.4) | 0.69 (0.49) | − 1.36 | 2.74 |